You are here
In an effort to continually explore the clinical possibilities for its highly innovative class of pharmaceuticals, Angiochem is pursuing research and development collaborations including platform, product, and academic collaborations.
Angiochem is considering collaborations with companies committed to developing drugs that reach beyond the blood-brain barrier and eager to access Angiochem’s proprietary technology and know-how to develop EPiC therapeutics to optimize their own proprietary molecules.
Similar to its collaboration with GlaxoSmithKline, Angiochem is continuing to discuss partnerships with potential collaborators who share Angiochem’s vision to bring novel therapeutics to the market and who are interested in licensing and further developing investigational drug candidates from the Angiochem pipeline.
Angiochem has established and will continue to establish research collaborations with government and academic research institutions to investigate the potential of its platform technology and EPiC drug candidates.
Interested in partnering with Angiochem?
Contact Angiochem Business Development at
514-788-7800 or by email.